Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
To study the efficacy and safety of icatibant in adult patients admitted to hospitalization
units for pneumonia caused by COVID-19, without mechanical ventilation, 10±1 days after
starting treatment or discharge from hospital if this occurs before 10 days.